|
Organovo is an early-stage medical laboratory and research company which designs and develops functional, three dimensional human tissue (also known as 3D bioprinting technology) for medical research and therapeutic applications. Organovo was established in 2007 and is headquartered in San Diego, California. The company uses its internally-developed NovoGen MMX Bioprinter for 3D bioprinting. == Operations == The company bioprints and markets human tissues as a means of accelerating the preclinical drug testing and discovery process, enabling treatments to be created more quickly and at lower cost, and without immediate risks to living test subjects. Organovo has long-term expectations that this technology could be suitable for surgical therapy and transplantation.〔(【引用サイトリンク】title=Utilizing Organovo Bioprinted Human Tissues in Research: living, three-dimensional human tissue models for research and therapeutic applications. )〕 Organovo also partners with biopharmaceutical companies and academic medical centers to design, build, and validate more predictive in vitro tissues for disease modeling and toxicology. The living test tissues provide researchers the opportunity to test drugs before administering the drug to a living person; this bridges the gap between preclinical testing and clinical trials. Organovo is actively developing its technology with the intention of eventually being able to replicate entire human organs for transplant. , the company's executive vice-president of commercial operations was Mike Renard. In 2015, Organovo signed an agreement to provide processes and technology to produce 3D printed human skin to L'Oreal for use in testing the safety and efficacy of cosmetic products. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Organovo」の詳細全文を読む スポンサード リンク
|